•pH-responsive microgels containing multifunctional ginsenoside Rh2-based liposomes remodel intestinal environment to enhance celastrol therapy for ulcerative colitis
•Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort
•Increased risk of de novo inflammatory bowel disease following cholecystectomy: a population-based analysis
•Nonconventional dysplasia in ulcerative colitis: a clinicopathological study of 694 patients
•Blood eosinophilia in patients with inflammatory bowel disease losing response to biologics